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Abstract
Background: Mammalian transcriptome contains a large proportion of diverse and structurally
complex noncoding RNAs. One class of such RNAs, natural antisense transcripts (NATs), are
derived from the opposite strand of many protein-coding genes. Although the exact structure and
functional relevance of most of the NATs is unknown, their emerging role as gene expression
regulators raises the hypothesis that NATs might contribute to development of complex human
disorders. The goal of our study was to investigate the involvement of NATs in regulation of
candidate genes for blood pressure.
Results: First we analysed blood pressure candidate genes for the presence of natural antisense
transcripts. In silico analysis revealed that seven genes (ADD3, NPPA, ATP1A1, NPR2, CYP17A1,
ACSM3,  SLC14A2) have an antisense partner transcribed from the opposite strand. We
characterized NPPA and its antisense transcript (NPPA-AS) in more detail. We found that NPPA-AS
is expressed in a number of human tissues as a collection of alternatively spliced isoforms and that
NPPA-AS and NPPA can form RNA duplexes in vivo. We also demonstrated that a specific NPPA-AS
isoform is capable of down-regulating the intron-retained NPPA mRNA variant. We studied the
evolutionary conservation of NPPA-AS and were able to detect the presence of Nppa-as transcript
in mouse.
Conclusion: Our results demonstrate functional interaction of NPPA-AS with NPPA at the RNA
level and suggest that antisense transcription might be an important post-transcriptional
mechanism modulating NPPA expression.
Background
A number of large-scale transcriptional mapping studies
have shown that the mammalian transcriptome is
extremely complex not only due to alternative splicing but
also (and maybe primarily) because of the abundance of
noncoding and often overlapping transcriptional units [1-
4]. This has raised the hypothesis of RNA-based regulatory
system that has allowed the elaboration and expansion of
phenotypic complexity of multicellular organisms [5]. It
appears that the transcription from both strands in
eukaryotic genomes is widespread [6-10], resulting in a
large pool of complementary RNAs, or natural sense-anti-
sense transcript pairs. The diversity and extent of antisense
transcription suggests that this may be an important and
common mechanism of gene expression modulation
(recently reviewed in [11-13]).
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Depending on the methodological approach and criteria
for antisense transcript detection, the estimates of the pro-
portion of transcripts involved in formation of sense-anti-
sense pairs varies from 20 to 40% [2,6-10]. Majority of the
natural antisense transcripts (NATs) originate from the
opposite DNA strand of the same locus as the sense tran-
script (cis-NATs). In some cases, NATs can be transcribed
from different loci on the genome (trans-NATs) [14].
Although high-throughput studies have investigated
expression pattern and evolution of antisense transcripts
on a genome-wide scale, the direct regulatory role of NATs
has been demonstrated only in a few cases. The mode of
NAT action includes very different mechanisms like tran-
scriptional interference [15], RNA masking [16], and epi-
genetic silencing by triggering heterochromatin formation
[17]. In addition, other double-stranded RNA dependant
mechanisms like RNA editing or RNA interference may be
involved. It has been shown that bidirectionally tran-
scribed loci in mouse can produce endogenous siRNAs
[14] and therefore may regulate gene expression by means
of RNAi. In the case of Zeb2 (zinc finger E-box binding
homeobox 2) expression regulation, a NAT masks one of
the 5' splice sites of Zeb2 pre-mRNA, thereby causing the
retention of regulatory intron that is necessary for the
translation of Zeb2 protein [16]. Strong phenotypic effect
of antisense transcription was shown in a specific case of
thalassemia which is caused by a deletion leading to aber-
rant antisense transcription and silencing of a neighbor-
ing gene by CpG island methylation [18]. The potential
role of NATs in the regulation of gene expression raises the
hypothesis that they might contribute to complex genetic
human disorders such as cardiovascular disease, cancer,
diabetes or mental disorders.
The goal of the present study was to investigate whether
natural antisense transcripts are involved in regulation of
candidate genes for hypertension. We proposed that the
functional variation of candidate genes might be affected
by the interaction with regulatory factors, including non-
coding antisense RNAs. We focused on the genes with
demonstrated role in familial forms of hypo- and hyper-
tension from a salt-water homeostasis pathway [19-21].
We identified seven genes that are associated with cis-
NATs (ADD3, NPPA, ATP1A1, NPR2, CYP17A1, ACSM3,
SLC14A2). Detailed analysis was carried out for NPPA
(natriuretic peptide precursor A) and its natural antisense
transcript, NPPA-AS. NPPA codes for a precursor of atrial
natriuretic peptide (ANP) that protects the cardiovascular
system from the volume and pressure overload by
decreasing vascular smooth muscle tone. Common
genetic variants at the NPPA locus that are associated with
the higher ANP concentration are also associated with
lower blood pressure and reduced risk of hypertension
[22]. In addition, NPPA  expression is tightly regulated
during the embryonic heart development [23,24], sug-
gesting that complex regulatory mechanisms control the
activity of NPPA.
Results
Natural antisense transcripts associated with candidate 
genes for blood pressure regulation
We first identified candidate genes [see Additional file 1 –
Table S1] with the evidence of antisense transcription by
screening them against published sense-antisense pairs
[8] and scanning for expressed sequence tags (ESTs) on
opposite strand using UCSC Genome Browser http://
genome.ucsc.edu/. We found that seven (ADD3, NPPA,
ATP1A1, NPR2, CYP17A1, ACSM3, SLC14A2) out of 38
genes tested had multiexon NATs supported by a number
of ESTs with canonical GT-AG splice donor-acceptor sites
(Table 1). The antisense transcripts (indicated by suffix -
AS, that stands for 'antisense') differ from each other in
their organization and complementarity in respect to
sense mRNA [see Additional file 2 – Figure S1]. The 5'-
most exons of antisense transcript for adducin 3, ADD3-
AS, have complementarity to 5' UTR exons of the sense
gene (5'-5' overlap). In other cases, the overlap pattern is
more complex, involving one or several internal exons
and intron-exon boundaries. In two cases, the transcript
from opposite strand has been annotated as a protein-
coding mRNA: (i) NPR2 3'-most exon is partially comple-
mentary to SPAG8 [see Additional file 2 – Figure S1D] and
(ii) EXOD1 is transcribed from opposite strand of ACSM3
[see Additional file 2 – Figure S1F]. In addition, the open
reading frame (ORF) is predicted for one of the isoforms
of  ADD3-AS  and  NPPA-AS  (99 and 121 amino acids,
respectively). Taken together, these data indicate that anti-
sense transcripts associated with blood pressure candidate
genes have diverse structure and various relationships to
their sense partners.
Structure and expression of NPPA in human tissues
For further studies we selected NPPA  and its antisense
transcript, NPPA-AS (Figure 1A). This sense-antisense pair
was selected for functional studies because (i) NPPA-AS is
represented by a cluster of alternatively spliced ESTs and
overlaps with the exons, introns as well as with intron-
exon boundaries of NPPA, raising the hypothesis that it
could have a posttranscriptional regulatory role in NPPA
expression and (ii) NPPA has a compact size, consisting of
only three exons and spanning ~2 kb on human chromo-
some 1p36.22 that makes it a good model system for
examination of the functional role of antisense transcrip-
tion.
We investigated the expression of NPPA using commercial
Human Multiple Tissue cDNA panels MTC I and II (Figure
1B, C). Consistent with previous studies [23-25], the
strongest expression of NPPA was detected in heart, butBMC Molecular Biology 2009, 10:81 http://www.biomedcentral.com/1471-2199/10/81
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several tissues contained additional alternative products.
Sequencing of these products revealed that the largest
NPPA band detected in many tissues (1820 bp) represents
the isoform of NPPA with retained both introns (further
referred to as NPPA+Intr1+2). Visual inspection of the aga-
rose gel (Figure 1B) indicates that the expression of this
unspliced form and correctly spliced NPPA appear to be
inversely correlated. Alternative product of 722 bp that
was observed in liver, testis and leukocytes contains the
retained intron 1 (NPPA+Intr1). In addition, a product
shorter than correctly spliced NPPA mRNA (457 bp) was
detected in testis. Sequencing of this product revealed that
its sequence and splicing pattern are similar to the tran-
scripts originating from the opposite strand, suggesting
that this is actually an isoform of NPPA-AS, which was not
represented by any of the ESTs in the database. To ensure
that the amplification of NPPA+Intr1+2 is not caused by
genomic DNA contamination, additional PCR experi-
ments were performed with several primers that detect
only NPPA-AS, but not NPPA [see Additional file 2 – Fig-
ure S2]. Because NPPA and NPPA-AS are both transcribed
from the same genomic locus, contamination with the
genomic DNA should result in amplification of unspliced
NPPA-AS as well. However, these reactions yielded only
the products corresponding to correctly spliced NPPA-AS,
indicating no presence of the genomic contamination and
demonstrating that the NPPA+Intr1+2  isoform indeed
represents mRNA with retained introns.
NPPA-AS is expressed as a collection of alternatively 
spliced isoforms
Next, we characterized the structure and expression profile
of NPPA-AS in human tissues using the panel of tissue-
specific cDNAs (Figures 1C, D). Sequencing of eight iden-
tified isoforms confirmed that they all are spliced accord-
ing to GT-AG consensus rule [see Additional file 2 –
Figures S3 and S4]. It appears that NPPA-AS isoforms are
not a result of alternative usage of different exons, but
rather almost every exon displays at least two alternative
splice donor/acceptor sites (Figure 1C). Majority of the
alternative splicing events occur at the acceptor site of the
intron. In addition, clearly identifiable polypyrimidine
tract is located close to the splice acceptor site of all
introns.
Next, we mapped the 3' end of NPPA-AS by RACE using
RNA from HeLa cell line. We designed the gene-specific
primers that would identify the 3' variants that are impor-
tant in respect of complementarity with NPPA. Sequenc-
ing of the 3' RACE products identified two alternative 3'
ends of NPPA-AS. One of the RACE products confirmed
the presence of 3'-terminal exon that was predicted based
on EST sequences CD368210 and BU732528 (3'RACE.1,
Figure 1C). In addition, we identified a novel 3'-terminal
exon that overlaps with the second intron and third exon
of NPPA (3'RACE.2, Figure 1C). Expression analysis of the
3'RACE.2 isoform showed that among the sixteen tissues
analysed, it is expressed only in testis (Figure 1D). Isoform
3'RACE.1 contains a suboptimal AGTAAA poly(A) signal
16 nucleotides upstream of the cleavage site, in the posi-
tion where the majority of poly(A) signals are located
[26]. 3'RACE.2 isoform does not contain a detectable
polyadenylation signal, but an A-rich element (AAAGA-
GAACACAGACATA), similar to the element found in
PAPOLG gene [27], that is also lacking any poly(A) signal
variant, is located 19 nucleotides upstream of polyade-
nylation site. This suggests that in addition to alternative
splicing, the processing of the NPPA-AS transcript might
be regulated also at the level of polyadenylation.
Table 1: Hypertension candidate genes associated with antisense transcripts.
Gene Antisense overlap* Antisense mRNA/ESTs§ Antisense ORF
ADD3(adducin 3)
chr10:111,746,098-111,885,313
2 exons, both 5' UTR U92992 (total 17 ESTs) 3 exons, 99 aa
NPPA (natriuretic peptide precursor A)
chr1:11,828,363-11,830,422
3 exons BU732528 (total 12 ESTs) 1 exon, 121 aa
ATP1A1 (Na+/K+ -ATPase alpha 1 subunit)
chr1:116,717,359-116,748,919
3 coding exons AK309389 (total 27 ESTs)
NPR2 (natriuretic peptide receptor B)
chr9:35,782,406-35,799,728
1 exon (coding and 3' UTR) SPAG8 (total 37 ESTs) 8 exons, 501 aa
CYP17A1 (cytochrome P450, family 17)
chr10:104,580,278-104,587,280
3 coding exons BX100578 (total 6 ESTs)
ACSM3 (acyl-coenzyme A synthetase)
chr16:20,682,813-20,715,980
1 coding exon EXOD1 (total 49 ESTs) 11 exons, 328 aa
SLC14A2 (solute carrier family 14, member 2)
chr18:41,046,958-41,517,058
1 noncoding 5' UTR exon AK126075 (total 12 ESTs)
* Number of sense gene exons involved in sense-antisense complementarity. § A gene symbol or a GenBank accession of a representative EST or 
mRNA and a total number of ESTs in antisense cluster. ORF – open reading frame (only ORFs larger than 90 aa are shown), UTR – untranslated 
region, aa – amino acids.BMC Molecular Biology 2009, 10:81 http://www.biomedcentral.com/1471-2199/10/81
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Splicing isoforms and expression pattern of NPPA and NPPA-AS Figure 1
Splicing isoforms and expression pattern of NPPA and NPPA-AS. (A) Genomic structure of NPPA and its antisense 
transcript, NPPA-AS (represented by several overlapping ESTs). Arrowheads indicate the direction of transcription, vertical lines 
depict the overlap between sense and antisense exons. The length of complementary region is shown in basepairs. Coding 
regions of NPPA and putative NPPA-AS ORF are represented as black boxes, noncoding exons and UTRs as white boxes. (B) 
The expression analysis of NPPA demonstrates the presence of intron-retained variants (NPPA+Intr1+2, 1820 bp and 
NPPA+Intr1, 722 bp) in a number of tissues. PCR reactions were performed using the primers NPPA-F and NPPA-R (indicated 
by arrows labeled F and R on Figure 1C) and resolved on an agarose gel. Expected size of correctly spliced NPPA product is 600 
bp. The shorter product in testis (457 bp) represents a testis-specific isoform of antisense transcript NPPA-AS.9, which was not 
represented by ESTs in the databank and therefore could not be avoided when designing primers. (C) The schematic depiction 
of NPPA and NPPA-AS splicing isoforms, the products of 3' RACE reactions and their location on the genomic sequence. The 
gray block arrows indicate the direction of transcription. (D) NPPA-AS is widely expressed as a complex combination of alterna-
tively spliced isoforms. Upper panel: the agarose gel showing the reactions performed using primers NPPA-AS-F4 and NPPA-
AS-R1 (indicated by arrows labeled F4 and R1 on Figure 1C) on the panel of tissue-specific cDNAs. Lower panel: Isoform 
3'RACE.2 is expressed only in testis. PCR was performed using primers NPPA-AS-F1 and NPPA-AS-R5 (indicated by arrows 
labeled F1 and R5 on Figure 1C). The band corresponds to the expected size of 405 bp.BMC Molecular Biology 2009, 10:81 http://www.biomedcentral.com/1471-2199/10/81
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Primary sequence of NPPA-AS is not evolutionarily 
conserved
To address the evolutionary conservation of NPPA-AS, we
first asked whether Nppa gene in mouse is associated with
similar natural antisense transcript. Two ESTs (Gen-
Bank:BQ771223 and CO043998 representing the 5' and
3' end of the IMAGE clone 6400656) at the Nppa locus
originate from the opposite strand and therefore may rep-
resent Nppa-as in mouse. These ESTs are isolated from the
brain of the mouse at embryonic day 12.5. Both ESTs fol-
low the GT-AG splicing consensus, and CO043998 con-
tains a canonical polyadenylation signal AATAAA as well
as a short poly(A) tail. RT-PCR using RNA isolated from
mouse tissues showed weak expression of Nppa-as  in
brain and very faint signal in liver (Figure 2A), while the
expression of Nppa was present in all tissues that were
tested (heart, brain, lung, liver, kidney and spleen) (Figure
2A). Exons of the mouse and human antisense transcript
are not conserved at the primary structure level outside of
the overlap regions with the NPPA exons and are located
at the different positions in the genomic sequence (Figure
2B). However, both in mouse and in human, the anti-
sense transcript overlaps with the intron-exon boundaries
of NPPA gene (Figure 2B).
The last exon of NPPA-AS 3'RACE.1 isoform (Figure 1C,
represented also by ESTs GenBank:CD368210 and
BU732528) contains an open reading frame (ORF) that is
predicted to code for a protein of 121 amino acids [see
Additional file 2 – Figure S5]. The multiple alignment and
in silico translation demonstrate that in all organisms
except human and chimpanzee, the predicted ORF is
interrupted by at least one frameshift and one stop codon
[see Additional file 2 – Figures S5A and S6]. Since the
translated amino acid sequence does not contain any con-
served domains and has no significant identity above 30%
to any known protein, the function of the predicted pro-
tein in human and chimpanzee cannot be assessed based
on the primary sequence.
Positive correlation between the expression levels of 
intron-retained NPPA and specific NPPA-AS isoforms
To study the correlation between the expression levels of
NPPA and NPPA-AS, we quantified the specific NPPA and
NPPA-AS isoforms using real-time PCR and commercial
Human Multiple Tissue cDNA panels MTC I and II (Figure
3). We focused on the NPPA-AS isoforms NPPA-AS.1 and
2 (Figure 3B) that are complementary to the first intron
and first and second exon of NPPA, including intron-exon
boundaries. These are the isoforms that most likely have
an impact on NPPA expression regulation. We detected no
correlation between the expression of correctly spliced
NPPA and its antisense transcript (Figure 3A), but instead
observed a strong positive correlation between the expres-
sion levels of NPPA-AS and NPPA variants with retained
intron 1 (Spearman's rank correlation coefficient = 0.77,
p-value = 0.0028). This result was confirmed by using an
alternative set of primers detecting the same NPPA-AS iso-
forms and retained NPPA intron 1 (data not shown). Such
correlation further indicates a possible functional rela-
tionship between NPPA-AS expression and posttranscrip-
tional regulation of NPPA.
NPPA-AS as a modulator of expression of NPPA splicing 
isoforms
To test the hypothesis that NPPA-AS has a regulatory role
in the splicing of NPPA mRNA, we constructed expression
vectors containing either NPPA gene or one of the four
antisense transcript isoforms with different regions of
complementarity to NPPA  (Figure 4A). Constructs
pNPPA-AS-1, -2, -3 and -4 were generated by cloning of
NPPA-AS isoforms NPPA-AS.1 and 2 and3'RACE products
Expression analysis of Nppa and Nppa-as in mouse tissues Figure 2
Expression analysis of Nppa and Nppa-as in mouse 
tissues. (A) Nppa is expressed in all tissues that were tested 
and Nppa-as is expressed in the brain. Nppa was amplified 
using primers mNppa-F and mNppa-R, Nppa-as was detected 
using primers mNppa-asF and mNppa-asR (indicated by 
arrows marked F, R, asF and asR on Figure 2B, respectively). 
(B) Genomic organization of NPPA locus in mouse and 
human. Arrowheads indicate the direction of transcription. 
Conservation profile of the human sequence, based on the 
UCSC vertebrate conservation track is shown below. Con-
servation is detected in the coding region (depicted as black 
boxes), promoter area and 3' terminus of NPPA gene, but not 
in the NPPA-AS exons that are located in introns or down-
stream of the NPPA gene.
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3'RACE.1 and 3'RACE.2, respectively, into the expression
vector pQM-Ntag/A. Generation of different constructs
expressing NPPA or NPPA-AS isoforms allows to test the
effect of each antisense variant separately and eliminates
the possible influence of transcriptional interference as a
mechanism of antisense action.
We cotransfected NPPA  expression construct into the
mouse embryonic fibroblast cell line NIH3T3 in pairs
with individual NPPA-AS constructs and quantified cor-
rectly spliced and intron-retained variants of NPPA  by
real-time RT-PCR. Mouse cell line was selected for trans-
fection in order to eliminate the possible effect of endog-
enous expression of NPPA and NPPA-AS. The expression
of specific NPPA-AS isoforms in transfected cells was con-
firmed by quantitative RT-PCR (data not shown). As
shown in Figure 4B, expression level of intron-retained
NPPA variant was significantly downregulated after trans-
fection with pNPPA-AS-1 (P = 0.002, Mann-Whitney test).
Although all constructs caused slight changes in expres-
sion levels of both spliced and intron-retained NPPA, the
effects did no reach statistical significance in other experi-
ments.
To further test whether complementary sequences of
NPPA and NPPA-AS actually can form RNA duplexes, we
performed RT-PCR on RNase treated RNA samples from
cotransfections of NPPA and NPPA-AS constructs pNPPA-
AS-1 and 3 (Figure 5). In both cases, the product with the
correct size from RNase-treated samples was obtained,
indicating that NPPA and its antisense transcript indeed
form duplex RNAs. pNPPA-AS-3 has complementarity
Expression levels of NPPA variants with retained intron and NPPA-AS are highly correlated (Spearman's rank correlation coeffi- cient = 0.77, p-value = 0.0028) Figure 3
Expression levels of NPPA variants with retained intron and NPPA-AS are highly correlated (Spearman's rank 
correlation coefficient = 0.77, p-value = 0.0028). (A) Expression levels of NPPA-AS (a total of isoforms 1 and 2) and NPPA 
(spliced and intron-retained forms were detected separately using primers shown on Figure 3B) were determined by quantita-
tive real-time PCR on a panel of human tissue-specific cDNAs. Expression levels were normalized to endogenous GAPDH 
mRNA. (B) Schematic depiction of primer positions (black arrows) that were used to quantify the expression levels of NPPA 
and NPPA-AS. To the right are indicated the symbols that are used for each reaction in Figure 3A.
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NPPA-AS constructs modulate the level of intron-retained NPPA variants Figure 4
NPPA-AS constructs modulate the level of intron-retained NPPA variants. (A) Schematic depiction of expression 
constructs and oligonucleotide primers that were used to quantify spliced NPPA (NPPA-Ex1Ex2-F and NPPA-Ex2-R) or the var-
iants with retained intron 1 (NPPA-In1Ex2-F and NPPA-Ex2-R). (B) The expression of NPPA intron-retained form was reduced 
significantly in case of coexpression with pNPPA-AS-1. Mouse NIH3T3 cells were cotransfected with pNPPA-mg2 along with 
different NPPA-AS expression constructs depicted above or empty vector as a control. Relative expression levels of spliced (left 
panel) and intron-retained (right panel) NPPA mRNA were analysed by real-time quantitative PCR. The geometric mean of two 
reference genes, GAPDH and HPRT1, was used as an endogenous control. The results are represented as arbitrary units based 
on relative quantity at the logarithmic scale. Error bars show s.e.m. P-value was calculated using Mann-Whitney Test.
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only to exonic regions of NPPA and can form a duplex
with both spliced and unspliced NPPA mRNA. In the case
of pNPPA-AS-1 we detected the duplex formation with the
intronic region of NPPA, which can occur only with
unspliced pre-mRNA. These results indicate that NPPA
and NPPA-AS interact at the RNA level and that a specific
NPPA-AS isoform (NPPA-AS.1) can modulate the propor-
tion of intron-retained NPPA.
Discussion
The important regulatory role of endogenous noncoding
RNAs, including antisense transcripts, has been proposed
based on a number of large-scale transcription profiling
studies. Because of the variety of functional mechanisms
and lack of direct experimental support, the biological
meaning of most of this noncoding transcription is still
unclear. In the present study we have investigated NPPA/
NPPA-AS sense-antisense transcript pair.
Several studies have addressed the question whether some
fraction of antisense transcripts may in fact be artifacts of
reverse transcription reaction [28,29]. To exclude such
artifacts from our study, we considered only NATs with
two or more exons and consensus splice sequences. In
addition, 3' RACE reactions further confirmed the strand-
specificity of NPPA-AS by identification of two alternative
polyadenylated 3' terminal exons (Figure 1C).
NPPA is a functional candidate gene for elevated blood
pressure, coding for an atrial natriuretic peptide (ANP), a
NPPA-AS forms RNA duplexes with NPPA Figure 5
NPPA-AS forms RNA duplexes with NPPA. Reactions were performed with cloned intron-containing NPPA gene (pNPPA-
mg2) and two antisense isoforms: pNPPA-AS-1 (A) and pNPPA-AS-3 (B). The agarose gels showing the results of PCR reac-
tions using RNA samples treated (+) or non-treated (-) with RNase A. RT indicates reverse transcription reaction in the pres-
ence (+) or without (-) a reverse transcriptase. H2O, no template control; Ctrl, control reaction performed using cloned NPPA 
(A) or NPPA-AS (B) as a template.
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member of a small family of endogenous peptide hor-
mones. It is produced primarily by atrial cardiocytes in
response to increasing cardiac wall tension. Association of
specific NPPA variants with increased ANP levels as well as
with lower blood pressure and reduced risk of hyperten-
sion [22] strongly support the central role of NPPA in the
maintenance of blood pressure homeostasis. In addition,
a region harbouring NPPA was among the eight loci iden-
tified in the meta-analysis of blood pressure genome-wide
association studies [30]. Transcriptional regulation of
NPPA and maturation of ANP have been studied quite
extensively (for recent reviews see [31,32]) and our results
add further evidence to the elaborate control of NPPA
expression.
During the expression analysis of NPPA mRNA we found
the strongest expression of correctly spliced NPPA in heart
and moderate expression in a number of human tissues,
including prostate, pancreas and small intestine, for
example (Figure 1B). In addition, we observed the expres-
sion of NPPA isoforms with retained introns (NPPA+Intr1
and NPPA+Intr1+2) in several tissues (Figure 1B). Nor-
mally, ANP is synthesized as a 153-amino acid preprohor-
mone. Removal of the signal peptide creates a 126-amino
acid prohormone that is further cleaved to form a mature
C-terminal 27-amino acid ANP. In the case of NPPA+Intr1
and  NPPA+Intr1+2, the ORF that starts with the first
methionine (Met-1) of prepro-ANP encodes only for a sig-
nal peptide region and is terminated after the frameshift
caused by the intron retention. An alternative ORF of
intron-retained NPPA isoforms, starting with the methio-
nine Met-51 includes the mature ANP sequence, but since
the peptide encoded by this putative ORF does not con-
tain a signal sequence, its proper processing and biologi-
cal activity is doubtful.
The natural antisense transcript of NPPA, that we named
NPPA-AS, is widely present in human tissues and displays
a complex pattern of alternative splicing (Figure 1D). All
different NPPA-AS splicing isoforms overlap with both
exonic and intronic regions of NPPA, including intron-
exon boundaries (Figure 1C). Such overlap pattern raised
the hypothesis that NPPA-AS may be involved in the reg-
ulation of NPPA expression.
Overlapping antisense gene pairs are preferentially co-
expressed or inversely expressed in human tissues
[6,33,34], supporting a model of negative control by anti-
sense RNA that proposes state of balance in case of co-
expression or up- or downregulation in case of inverse
expression. Interestingly, the expression of NPPA-AS was
strongly correlated with the intron-retained, rather than
correctly spliced form of NPPA (Figure 3), indicating that
it may play a functional role in posttranscriptional regula-
tion of NPPA expression. Such correlation, however, does
not necessarily indicate causal relationship, because it can
be affected by many factors including regulation of tran-
scription of both NPPA and NPPA-AS, or modulation of
NPPA splicing by other factors.
Conservation often reflects functional significance of a
nucleotide sequence. Among sense-antisense pairs, less
than 7% are found to be conserved between human and
mouse [35,36]. This may indicate that antisense tran-
scripts are mostly species-specific, or alternatively, that the
process of transcription, secondary structure or organiza-
tion of the transcript rather than the primary sequence is
functionally important. Among conserved sense-antisense
pairs, about one third have identical expression pattern in
mouse and human [37]. We found that expression profile
in mouse and human is different for both NPPA  and
NPPA-AS (Figure 2). In mouse, Nppa is strongly expressed
in some tissues (brain, lung, liver) where human NPPA is
expressed weakly. We did not detect any alternatively
spliced or intron-retained Nppa forms in mouse. In case of
NPPA-AS, we found that neither the primary structure nor
the expression pattern is conserved between mouse and
human: in human it is expressed in all tissues examined,
while in mouse the expression was observed only in brain
(Figure 2A). However, both mouse and human antisense
transcripts overlap with the exon-intron boundaries of
NPPA (Figure 2B), implying that such genomic arrange-
ment might be functionally significant.
Although many antisense transcripts overlap with the
intron-exon boundaries of the sense mRNA, the effect of
endogenous antisense transcripts as splicing regulators is
studied in detail only in a few cases [16,38]. Modulation
of mRNA splicing by exogenous antisense oligonucle-
otides has gained more attention and its therapeutic
potential has been established in clinical trials involving
patients with Duchenne's muscular dystrophy [39]. Much
less is known about the role of endogenous antisense
RNAs in regulation of splicing or stability of different
mRNA isoforms. The complementarity of NPPA and its
antisense exons suggests that if NPPA-AS has a function in
regulation of NPPA, it depends on the mechanisms that
involve the interactions at the RNA level. Our results show
(Figure 4B) that at least one NPPA-AS isoform can modu-
late the ratio of unspliced and spliced NPPA variants, by
decreasing the levels of intron-retained NPPA form. Since
we were using minigene expression system, we excluded
the effects of such possible regulatory mechanisms like
transcriptional interference and heterochromatin forma-
tion [17]. Currently we do not know what is the exact
mechanism of intron-retained NPPA downregulation, but
it is possible that the formation of the duplex RNA due to
the complementary regions can lead to post-transcrip-
tional regulation via different mechanisms like RNA
masking (in which case the binding of factors required forBMC Molecular Biology 2009, 10:81 http://www.biomedcentral.com/1471-2199/10/81
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splicing or export is blocked), RNA editing or RNA inter-
ference [14]. Although the role of RNA interference in
NAT-mediated regulation in mammals has been contro-
versial, Watanabe et al. [14] identified seventeen loci in
mouse where siRNAs arose from interaction of sense-anti-
sense transcripts of the same locus. Considering the large
number of NATs in mammals, the real extent of siRNA
biogenesis via endogenous sense-antisense RNA interac-
tion in mammalian cells remains still unknown. It is also
possible that since antisense transcription extends
through entire NPPA locus and into the promoter region,
the mechanisms like transcriptional interference and
modulation of NPPA promoter elements can occur and
affect the expression of NPPA independently.
Although the biological role of NPPA antisense transcrip-
tion needs further investigation, the regulatory role of
NPPA in both adult cardiovascular system and in heart
development during embryogenesis [23,24] suggest that
NPPA-AS may be involved in fine-tuning of NPPA expres-
sion during embryonic development or in response to
specific stimulus.
Conclusion
We have identified the natural antisense transcripts of
human blood pressure candidate genes and provide a
detailed characterization of an antisense transcript associ-
ated with the NPPA gene. Our data support the biological
significance of NPPA-AS by demonstrating that it (i) is
widely expressed as a collection of canonically spliced iso-
forms, (ii) can directly interact with NPPA at the RNA level
and (iii) is able to influence the levels of intron-retained
NPPA variants.
Methods
Identification and in silico analysis of natural antisense 
transcripts
Candidate genes (n = 38) were selected according to the
prior evidence of involvement in blood pressure regula-
tion [see Additional file 1 – Table S1]. Most of the genes
were selected based on the published data on the biology
and genetics of blood pressure regulation. The selection
included also genes responsible for the Mendelian forms
of hypertension or hypotension, location near linkage
peaks or quantitative trait loci (QTLs), reports on animal
models and human association studies. Additional infor-
mation was obtained from different resources (OMIM,
http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim;
NCBI GeneBank and NCBI Locuslink http://
www.ncbi.nlm.nih.gov/; Ensembl http://
www.ensembl.org/index.html). Candidate gene list was
also supplemented with loci involved in other cardiovas-
cular diseases like myocardial infarction, coronary artery
disease and stroke. The candidate genes were screened for
antisense transcripts using recently published sense-anti-
sense transcript data [8]. The structure and direction of the
transcripts was verified using UCSC Genome Browser
http://genome.ucsc.edu/. To avoid random „transcrip-
tional noise” and genomic DNA contamination, we con-
sidered only transcripts with at least two exons, canonical
splice sites (GT/AG) and overlap with at least one exon of
the sense gene. In addition, several transcripts had a poly-
adenylation signal and poly(A) tail, supporting together
with canonical splice sites their strand-specificity.
Multiple alignment of sequences corresponding to pre-
dicted ORF of NPPA-AS from different species was per-
formed using ClustalW2 at http://www.ebi.ac.uk/Tools/
clustalw2/index.html. Sequence database searches were
performed using BLAST programs at http://
www.ncbi.nlm.nih.gov/.
PCR and sequencing
Expression analysis of NPPA and NPPA-AS was carried out
using Human Multiple Tissue cDNA panels MTC I and II
(BD Biosciences) and primers [see Additional file 1 –
Table S2] that were designed using Primer3 program
http://frodo.wi.mit.edu/. G3PDH primers were included
with MTC panels. PCR on mouse tissue-specific cDNAs
was performed using oligonucleotides designed according
to mouse Nppa gene and EST BQ771223 (for Nppa-as).
PCR conditions were: 75 mM Tris-HCl (pH 8.8), 20 mM
(NH4)2SO4, 0.01% Tween 20, 2.5 mM MgCl2, 250 μM
dNTPs and 2.5 u per 100 μl Taq DNA Polymerase (Fer-
mentas). Cycling conditions followed the touch-down
procedure, namely initial denaturation at 94°C for 2 m,
followed by 11 cycles at 94°C for 30 s, annealing for 30 s
at temperatures decreasing from 62 to 57°C (with 0.5°C
decremental in each cycle), 72°C for 60 s, and 30 cycles at
94°C for 30 s, 57°C for 30 s, 72°C for 60 s, and ending
with an extension step at 72°C for 5 m.
For sequencing, PCR products were extracted from agar-
ose gel using NucleoSpin Extract II (Macherey-Nagel) and
either cloned into the pTZ57R vector using InsT/Aclone
Kit (Fermentas) or sequenced directly after ExoI/SAP
(both Fermentas) treatment. Sequencing reactions were
performed using BigDye Terminator v3.1 Cycle Sequenc-
ing Kit (Applied Biosystems) according to manufacturer's
instructions and analyzed on ABI Prism™ 3730xl DNA
Analyzer. Sequencing results were manually analyzed
using Bioedit software http://www.mbio.ncsu.edu/
BioEdit/bioedit.html and mapped to the genome using
BLAT alignment tool [40] at the UCSC Genome Browser
http://genome.ucsc.edu/. Novel sequences obtained in
this study have been submitted to GenBank database
(FJ706070–FJ706079).
3' RACE (rapid amplification of cDNA ends)
The 3' RACE reactions were performed using GeneRacer™
Kit (Invitrogen) and 1 μg of total RNA isolated from semi-
confluent HeLa cells grown in 5% CO2 at 37°C. ReverseBMC Molecular Biology 2009, 10:81 http://www.biomedcentral.com/1471-2199/10/81
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transcription was performed using SuperScript III Reverse
Transcriptase and GeneRacer™ Oligo dT Primer (both
included in the kit). Amplification was carried out using
GeneRacer™ or 3' primer and the following gene-specific
primers: NPPA-AS-F1, -F2 or -F5. Nested PCR was per-
formed using nested GeneRacer™ primer and suitable
gene-specific primers.
Construction of plasmids
The vector pQM-Ntag/A (Quattromed, Estonia) was used
to create expression constructs under the control of CMV
promoter.  NPPA  gene was amplified from human
genomic DNA using primers NPPA-GFXba and NPPA-
GRBam and inserted into the XbaI and BamHI sites of
pQM-Ntag/A. These primers amplify a 2069 bp fragment
(chr1:11828358-11830426 according to human genome
assembly hg18) of genomic DNA, including all three
NPPA coding exons and both UTRs. Four constructs rep-
resenting different NPPA-AS splicing isoforms were gener-
ated. pNPPA-AS-1 and -2 represent splicing isoforms
NPPA-AS.1 and NPPA-AS.2 obtained with oligonucle-
otides NPPA-AS-F4 and NPPA-AS-R1. For generation of
pNPPA-AS-3 and -4, 3' RACE products 3'RACE.1 and
3'RACE.2 were utilized. All constructs were sequenced
using internal primers as well as universal primers flank-
ing the insert cloning site.
Transfection of expression constructs
Cells were grown in 5% CO2 at 37°C and on the day
before transfection were plated into 24-well plates using
medium without antibiotics. Next day, cells were trans-
fected using Lipofectamine™ 2000 reagent (Invitrogen)
and 1.0 μg of total plasmid DNA (0.2 μg of pNPPA-mg2
and 0.8 μg of any of the NPPA-AS constructs or empty vec-
tor). Cells were incubated at 37°C and RNA was isolated
24 hours later. For relative quantitation experiments,
transfections were carried out in triplicate three times
(total nine replicates).
RNA isolation
Total RNA from cell lines and from mouse (male C57bl/
6) tissues was isolated using TRIzol reagent (Invitrogen)
and the quantity and quality of RNA was assessed using
Nanodrop ND-1000 (Thermo Scientific). DNase treat-
ment was performed using TURBO DNA-free Kit™
(Ambion) with 1 μg of RNA in a volume of 30 μl. cDNA
was synthesized using 2 μg of total RNA and First Strand
cDNA Synthesis Kit (Fermentas) according to manufac-
turer's instructions.
Real-time quantitative PCR
For investigation of expression levels of NPPA and NPPA-
AS in human tissues, the Human Multiple Tissue cDNA
panels MTC I and II (BD Biosciences) were used. Amplifi-
cation was performed with the following primer pairs:
NPPA-Ex1Ex2-F and NPPA-Ex2-R for quantification of
spliced NPPA; NPPA-In1Ex2-F and NPPA-Ex2-R for detec-
tion of unspliced NPPA. For quantification of NPPA-AS,
primers NPPA-ASRT-F4 and NPPA-ASRT-R4 were used.
GAPDH was used as an endogenous control and ampli-
fied with primers GAPDH-S and GAPDH-AS. For quanti-
fication of spliced and unspliced NPPA from transfection
experiments, RNA from mouse NIH3T3 cells was isolated
and DNase-treated as described above. Primers were
designed avoiding binding to mouse sequences to prevent
nonspecific amplification. Correctly spliced NPPA mRNA
was detected using primers NPPA-Ex1Ex2-F and NPPA-
Ex2R, unspliced NPPA was detected using primers NPPA-
In1Ex2-F and NPPA-Ex2-R. Two endogenous reference
genes were used: GAPDH  (amplified with primers
GAPDH-S and GAPDH-AS) and HPRT1 (amplified with
primers HPRT1-S and HPRT1-AS). The reactions were per-
formed in the 96-well microtiter plate using ABI PRISM®
7900 Real-Time PCR cycler. The 25 μl reaction mixture
consisted of 3 μl of 1:10 cDNA dilution, 12.5 μl of ABso-
lute™ QPCR SYBR® Green ROX Mix (Thermo Scientific),
70 nM forward and reverse primer. The cycling parameters
were: enzyme activation at 95°C for 15 m followed by 40
cycles 95°C for 15 s, 60°C for 30 s, 72°C for 30 s. Reac-
tions were performed in triplicates for each biological rep-
licate. As negative controls for DNA contamination,
reactions without the reverse transcriptase were carried
out. We performed control and optimization experiments
for all primer pairs and selected for actual quantitation
experiments primer pairs with amplification efficiency of
100 ± 10%. During optimization, serial dilutions of tem-
plate were used and the specificity of the PCR products
was confirmed by the presence of a single peak during the
dissociation curve analysis. Amplification efficiency of the
reactions was 100 ± 10% and intra- and inter-assay varia-
tion coefficients were below 3% and 8%, respectively.
PCR efficiencies were calculated from ten-fold dilution
series and relative expression of correctly spliced and
intron-retained NPPA was calculated according to Pfaffl
[41] by taking PCR efficiency into account. The geometric
mean of GAPDH and HPRT1 was used as an endogenous
control. Statistical significance of the results was analyzed
using two-tailed Mann-Whitney test.
Duplex detection
RNA from NIH3T3 cells cotransfected with constructs
pNPPAmg2 and pNPPA-AS-1 or pNPPA-AS-3 was isolated
as described previously and treated with DNase (TURBO
DNA-free Kit™, Ambion) according to manufacturer's
instructions and 0.5 μl of RNase A (10 mg/ml, Fermen-
tas). RNase was inactivated with 0.5 mg/ml proteinase K
treatment at the presence of 1% SDS for 30 min at 37°C.
RNA was extracted with phenol/chloroform treatment
and cDNA was synthesized using primers In1R (for NPPA-
AS-1 duplex detection) or duplR (for NPPA-AS-3) andBMC Molecular Biology 2009, 10:81 http://www.biomedcentral.com/1471-2199/10/81
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First Strand cDNA Synthesis Kit (Fermentas). In parallel,
control experiments using RNAs not treated with RNase A
and reverse transcriptions without reverse transcriptase
were performed. PCR was performed with primers In1R
and Ex1In1F for detection of NPPA::NPPA-AS-1 duplex
and with primers duplF and duplR for detection of
NPPA::NPPA-AS-3 duplex.
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